Compared side by side

Semaglutide vs amycretin: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Semaglutide activates one receptor, GLP-1; amycretin, also from Novo Nordisk, is one peptide that switches on the GLP-1 receptor and the amylin receptors, so it adds fullness after meals to GLP-1’s appetite signal. Semaglutide is FDA-approved for type 2 diabetes and weight management, as Ozempic and Wegovy; amycretin has been in phase 3 since February 2026 and isn’t approved anywhere. In their own trials, semaglutide averaged about 15% weight loss at 68 weeks, and weekly amycretin shots took off about 22% at 20 mg and 24% at 60 mg over 36 weeks in a small phase 1b/2a trial.

Side by side

ComparedSemaglutideAmycretin
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asOzempic, WegovyZenagamtide, NNC0487-0111, Amy
What it isA GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying.One peptide from Novo Nordisk that gives both the GLP-1 and the amylin signal, the pair CagriSema delivers as two drugs, as a weekly shot or a daily tablet.
How it worksGLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects.One peptide that switches on both the GLP-1 receptor and the amylin receptors (and the calcitonin receptor), so it carries the two signals CagriSema gives as two drugs. GLP-1 curbs appetite and slows the stomach; amylin adds fullness after meals. A fatty-acid side chain binds it to albumin in the blood, so a weekly shot lasts. Novo Nordisk is developing it as a weekly injection and as a daily tablet. Investigational, in phase 3 since February 2026.
Commonly reportedThe constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.In trials, strong appetite loss and GI side effects during the step-ups. Now named zenagamtide; in phase 3 and not approved anywhere.
Studied rangeFDA label: 0.25–2.4 mg, starting dose 0.25 mg.Research range: 0.4–60 mg, starting dose 0.2 mg. Studied in research — not a recommendation.
How oftenWeekly SubQWeekly
Half-life~1 week (FDA label)~88 hours (measured in people: 88.1 h after a single 0.3 mg SubQ dose with normal kidney function; Oldenburg 2026)
RouteSubQ injectionSubQ injection
Typical runFDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers.Used continuously, once weekly, in its trials: up to 36 weeks so far, with doses stepped up every 4 weeks. No trial has tested stopping it.
EvidenceEstablished: clinical trials or FDA-approved use existsModerate: animal studies + some human data
Common side effectsNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis riskNausea, vomiting, diarrhea, decreased appetite

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking semaglutide or amycretin? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Semaglutide

  • Day 1–28 · 0.25 mg Gut is adapting
  • Day 29–56 · 0.5 mg Appetite shifts are real now
  • Day 57–112 · 1 mg Clinically useful weight loss kicks in
  • Day 113–140 · 1.7 mg Max submaximal step
  • Day 141–364 · 2.4 mg Full dose — the working dose
  • Day 365+ Plateau territory — new baseline

Every card for semaglutide, with its sources

Amycretin

  • Day 1–28 A very low start
  • Day 57–140 · 1.25 mg The lowest dose tested for weight
  • Day 85–252 With type 2 diabetes
  • Day 113–196 · 5 mg Five milligrams
  • Day 169–252 · 20 mg Twenty milligrams
  • Day 253+ A long-term medicine, not a course

Every card for amycretin, with its sources

Questions people ask

How long do semaglutide and amycretin last?

The half-life of semaglutide is ~1 week (FDA label). The half-life of amycretin is ~88 hours (measured in people: 88.1 h after a single 0.3 mg SubQ dose with normal kidney function; Oldenburg 2026).

How often are semaglutide and amycretin taken?

Semaglutide: weekly SubQ. Route: SubQ injection. Amycretin: weekly. Route: SubQ injection.

How are semaglutide and amycretin dosed in research?

The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose. The research range for amycretin is 0.4–60 mg, with a 0.2 mg starting dose. Studied in research — not a recommendation.

What are the common side effects of semaglutide and amycretin?

For semaglutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk. For amycretin: nausea, vomiting, diarrhea, decreased appetite.

Each one in full

Track it in the app

PepVault for iPhone

Taking semaglutide or amycretin? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo